Brand Intelligence Graphcompany
Company Overview
About Viatris
Viatris Inc. is a global pharmaceutical company formed in 2020 through the combination of Pfizer's off-patent branded drug unit (Upjohn) and Mylan, one of the world's largest generic drug manufacturers. The company manufactures, licenses, and distributes approximately 1,400 approved molecules across branded generics, complex generics, and a portfolio of iconic off-patent brands including Lipitor (atorvastatin), Viagra (sildenafil), EpiPen, and Xanax (alprazolam) sold in markets where these brands retain meaningful recognition and premium pricing.
Business Model & Competitive Advantage
Viatris reported approximately $15.4 billion in revenue in FY2024, with results shaped by the expected base erosion of its branded generics portfolio and management's aggressive capital allocation program. The company divested several non-core assets including its biosimilars business (sold to Biocon Biologics), women's health portfolio, and API manufacturing assets, using proceeds to reduce a substantial debt load inherited from the merger and fund share repurchases. Complex generics — inhalers, injectables, ophthalmic products requiring specialized manufacturing — represent the future revenue mix.
Competitive Landscape 2025–2026
Viatris's strategic rationale centers on addressing unmet medical needs in markets where affordability matters — emerging markets where branded drug access is limited, and in the U.S. where generic substitution saves the healthcare system billions annually. The company's global manufacturing network in 40+ countries gives it a cost structure and regulatory footprint that few pure-play generics companies can match. Long-term value creation depends on successfully launching complex generics to offset branded portfolio erosion.
Recent Activity
View all →Key Differentiators
Market Leader
Viatris is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $15.4B in revenue, Viatris operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
West Pharmaceutical Services
West Pharmaceutical Services, Inc. is the global leader in packaging components and delivery systems for injectable medications, designing and manufacturing the stoppers, closures, caps, and drug deli
Compare Viatris with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Viatris? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Viatris Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Viatris vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →